Attached files

file filename
8-K - FORM 8-K - Shire plcdp21465_8k.htm
EX-99.3 - EXHIBIT 99.3 - Shire plcdp21465_ex9903.htm
EX-99.1 - EXHIBIT 99.1 - Shire plcdp21465_ex9901.htm
 
Press Release
www.shire.com
 
 
Total Voting Rights
 
March 1, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,  in accordance with DTR 5.6.1 of the FSA’s Disclosure and Transparency Rules, notifies the market of the following:

At close of business on February 28, 2011, Shire plc's issued voting share capital consisted of 562,231,558 ordinary shares with a nominal value of 5 pence.  Each ordinary share carries one voting right.  Shire plc does not hold any shares in Treasury.

The above figure (562,231,558) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Shire plc under the FSA's Disclosure and Transparency Rules.
 
Tony Guthrie
 
Deputy Company Secretary
 
 
For further information please contact:

Investor Relations
   
Eric Rojas
erojas@shire.com
+1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX